Human Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]-Evobrutinib

Inclusion Criteria: * Participants are overtly healthy as determined by medical evaluation, including medical history, physical examination, laboratory tests, and cardiac monitoring * Have a body weight within 50.0 to 120.0 kilogram (kg) (inclusive) and body mass index within the range 19.0 - 30.0 kilogram per meter square (kg/m\^2) (inclusive) * Male participants agree to be consistent with local regulations on contraception methods * Can give signed informed consent * Other protocol defined inclusion criteria could apply Exclusion Criteria: * History or presence of clinically relevant respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, connective tissue diseases or disorders * Prior history of cholecystectomy or splenectomy, and any clinically relevant surgery * Any surgical or medical condition which might significantly alter the ADME of drugs * History of any malignancy, chronic or recurrent acute infection * History of shingles * History of drug hypersensitivity ascertained or presumptive allergy/hypersensitivity to the active drug substance and/or formulation ingredients * History of alcoholism or drug abuse * History of residential exposure to tuberculosis, or a positive QuantiFERON test at screening * Administration of live vaccines or live-attenuated virus vaccines * Any condition, including findings in the laboratory tests, medical history, or other screening assessments, that in the opinion of the Investigator constitutes an inappropriate risk or a contraindication for participation in the study or that could interfere with the study's objectives, conduct, or evaluation * Prior/concomitant therapy * Relevant radiation exposure * Clinically relevant findings (excluding minor deviations) in biochemistry, hematology, coagulation and urinalysis * Vital signs (pulse rate and blood pressure) outside the normal range * Estimated Glomerular Filtration rate according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) * Semi supine systolic blood pressure (SBP) greater than (\>) 140 millimeters of Mercury (mmHg) or less than (\<) 90 mmHg, diastolic blood pressure (DBP) \> 90 mmHg or \< 45 mmHg and pulse rate \>= 100 bpm or =\< 40 bpm, at admission * 12-Lead electrocardiogram (ECG) showing a QTcF \> 450 millisecond (ms), PR \> 215 ms, or QRS \> 120 ms * Positive for hepatitis B surface antigen (HBsAg), hepatitis B core antibody, hepatitis C antibody, or human immunodeficiency virus (HIV) I and II tests at screening * Other protocol defined exclusion criteria could apply